Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198889 | 1.00 | TSHR (0.44) | TSHRLPAR1LPAR2LPAR3THRB | |
| SCHEMBL202073 | 1.00 | TSHR (0.44) | TSHRLPAR1LPAR2LPAR3THRB | |
| SCHEMBL198971 | 1.00 | TSHR (0.44) | TSHRLPAR1LPAR2LPAR3THRB | |
| SCHEMBL984915 | 1.00 | TSHR (0.44) | TSHRLPAR1LPAR2LPAR3THRB | |
| SCHEMBL198374 | 1.00 | TSHR (0.44) | TSHRLPAR1LPAR2LPAR3THRB | |
| SCHEMBL980876 | 1.00 | TSHR (0.44) | TSHRLPAR1LPAR2LPAR3THRB | |
| SCHEMBL199294 | 1.00 | TSHR (0.44) | TSHRLPAR1LPAR2LPAR3THRB | |
| SCHEMBL198324 | 1.00 | TSHR (0.44) | TSHRLPAR1LPAR2LPAR3THRB | |
| SCHEMBL198791 | 1.00 | TSHR (0.44) | TSHRLPAR1LPAR2LPAR3THRB | |
| SCHEMBL199845 | 1.00 | TSHR (0.44) | TSHRLPAR1LPAR2LPAR3THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023080258-A1 | CARBONYL COMPOUND, METHOD FOR PRODUCING CARBONYL COMPOUND, METHOD FOR PRODUCING ISOCYANATE COMPOUND, AND ISOCYANATE COMPOSITION | 旭化成株式会社 | 2023-05-11 | — | — | WO | disclosed |
| WO-2023080257-A1 | METHOD FOR PRODUCING ISOCYANATE COMPOUNDS, METHOD FOR PRODUCING CARBAMATE COMPOUNDS, METHOD FOR RECOVERING AMINE COMPOUNDS, AND ISOCYANATE COMPOSITION | 旭化成株式会社 | 2023-05-11 | — | — | WO | disclosed |
| EP-2275406-B1 | PROCESS FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2018-11-28 | — | — | EP | disclosed |
| EP-1655291-B1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-9233918-B2 | Isocyanate production process | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-01-12 | — | — | US | disclosed |
| CN-103130739-B | There is the compound of thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2015-09-16 | — | — | CN | disclosed |
| CN-102796058-B | Compound having thrombopoietin receptor agonism | SHIONOGI & CO | 2015-05-13 | — | — | CN | disclosed |
| US-8481736-B2 | Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof | BASF SE (DE) | 2013-07-09 | — | — | US | disclosed |
| CN-103130739-A | Compounds having thrombopoietin receptor agonism | SHIONOGI & CO | 2013-06-05 | — | — | CN | disclosed |
| EP-2088138-B1 | Process for producing isocyanate | ASAHI KASEI CHEMICALS CORP (JP) | 2013-02-27 | — | — | EP | disclosed |
| EP-2088138-A1 | PROCESS FOR PRODUCING ISOCYANATE | Asahi Kasei Chemicals Corporation (JP) | 2009-08-12 | — | — | EP | disclosed |
| CN-101467276-A | Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof | MAX PLANCK GESELLSCHAFT (DE) | 2009-06-24 | — | — | CN | disclosed |
| EP-2029573-A1 | DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS | BASF SE (DE) | 2009-03-04 | — | — | EP | disclosed |
| EP-2008319-A2 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007138051-A1 | DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS | BASF SE (DE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007116001-A2 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2007-10-18 | — | — | WO | disclosed |
| EP-1843407-A1 | Liquid crystalline rylenetetracarboxylic acid derivatives and their use | BASF AKTIENGESELLSCHAFT (DE) | 2007-10-10 | — | — | EP | disclosed |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2007-02-22 | — | — | US | disclosed |
| CN-1863783-A | Compounds with Thrombopoietin Receptor Agonism | SHIONOGI & CO (JP) | 2006-11-15 | — | — | CN | disclosed |
| EP-1655291-A1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2006-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | DHFR, NAT1, ACR | TSHR 757/4885LPAR1 819/4885LPAR2 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.